# OnCo record all-infant (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/all-infant/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "all-infant" ;
  schema:name "Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)"@en ;
  schema:alternateName "Infant ALL"@en, "KMT2A-rearranged infant leukaemia"@en, "MLL-rearranged infant ALL"@en ;
  schema:description "Leukaemia diagnosed in the first year of life is a different disease from leukaemia in older children: most cases carry a broken KMT2A gene and respond poorly to chemotherapy, and fewer than half of infants were cured for twenty years. One course of the immune drug blinatumomab after induction raised two-year disease-free survival from about half to over 80 percent in a pilot study."@en ;
  schema:url <https://onco.cc/cancers/all-infant/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia> ;
  schema:citation <https://en.wikipedia.org/wiki/Acute_lymphoblastic_leukemia>, <https://www.cancer.gov/types/leukemia/hp/child-all-treatment-pdq> ;
  onco:tag "subtype-page", "paediatric" ;
  onco:related <https://onco.cc/cancers/aml-npm1-kmt2a/>, <https://onco.cc/cancers/all-paediatric-relapsed/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/menin-inhibitors/>, <https://onco.cc/technologies/allogeneic-hsct/> ;
  onco:targets <https://onco.cc/targets/kmt2a/>, <https://onco.cc/targets/menin/>, <https://onco.cc/targets/cd19/> ;
  onco:pathways <https://onco.cc/pathways/menin-kmt2a/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/efs/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-augment-101-revumenib-menin-nature-2023/>, <https://onco.cc/key-papers/paper-interfant-06-pieters-jco-2019/>, <https://onco.cc/key-papers/paper-blinatumomab-infant-all-van-der-sluis-nejm-2023/>, <https://onco.cc/key-papers/paper-interfant-99-lancet-2007/> ;
  onco:pipeline <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/technologies/menin-inhibitors/>, <https://onco.cc/ideas/idea-menin-infant-all/>, <https://onco.cc/trials/augment-101/> ;
  onco:standardOfCare <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/daunorubicin/>, <https://onco.cc/drugs/asparaginase/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/trials/interfant-06/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/trials/interfant-06/>, <https://onco.cc/drugs/cytarabine/>, <https://onco.cc/drugs/methotrexate/>, <https://onco.cc/drugs/mercaptopurine/>, <https://onco.cc/targets/kmt2a/>, <https://onco.cc/technologies/allogeneic-hsct/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/revumenib/>, <https://onco.cc/drugs/ziftomenib/>, <https://onco.cc/drugs/blinatumomab/>, <https://onco.cc/drugs/tisagenlecleucel/>, <https://onco.cc/trials/augment-101/>, <https://onco.cc/ideas/idea-menin-infant-all/>, <https://onco.cc/technologies/allogeneic-hsct/> .